(Reuters) -The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE’s blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option of at-home self administration, the company said on Thursday.
(Reporting by Kamal Choudhury and Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Alan Barona)
Brought to you by www.srnnews.com
